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ABSRTACT 
 
 
 
L'eficiència de l'encapsulació i el alliberamentt de medicaments en microcàpsules de fàrmacs 
solubles amb quitosan estan directament influïts per molts factors durant el procés que 
encara no s'han estudiat. 
L'objectiu d'aquest projecte és fer una primera aproximació a la influència de les variables 
del procés com la concentració dels components de les microcàpsules, els temps d'agitació, 
la temperatura del procés, les relacions molars i moltes altres variables. 
En aquest projecte, diverses combinacions d’aquestes variables s’han provat i analitzat 
posteriorment per tal de comparar els seus resultats i tenir una primera visió de la influència 
de cada variable. 
També s’ha estudiat i analitzat l’assaig per a l’alliberament de fàrmacs per veure l’efecte de 
diferents teixits en diferents mostres de microcàpsules i modelat per aconseguir un 
alliberament controlat de fàrmacs. 
 
 
 
 
 
 
 
 
 
 
  
ABSTRACT 
 
The encapsulation efficiency and the drug delivery of microcapsules of soluble drugs with 
chitosan is directly influenced by many factors during the process that have not been 
studied yet. 
The aim of this project is to make a first approach of the influence of the variables of the 
process as the concentration of the components of the microcapsules, the stirring times, the 
process temperature, molar ratios and many other variables. 
In this project, several combinations of this variables have been tested and analyzed 
afterwards in order to compare their results and have a first view of the influence of each 
variable. 
Also the drug delivery essay have been studied and analyzed to see the effect of different 
fabrics in different samples of microcapsules, and modeled for achieving a controlled drug 
release.  
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1. INTRODUCTION 
 
The humanity desire to keep improving in every scientific field has led science and 
engineering to find new solutions and materials with unimaginable properties or 
functionalities that could not be imagined years before. 
One of this fields to improve is microencapsulation, since is a relatively recent science and 
has still a lot of way to go in developing and improving terms, for instance, the improvement 
of the biocompatibility of the microcapsules inasmuch as many of the uses of microcapsules 
are destined to biomedicine or fields in touch with the human body, the achievement of 
encapsulating a vast variety of materials, as each of them has different behaviors in the 
encapsulation process and need specific conditions to reach a certain percentage of 
encapsulation. 
Biocompatible polymers are a rising field since many illness or conditions require a constant 
level of medicaments or agents in vivo to provide the most effective prophylactic, 
therapeutic or diagnostic results. This dosage of medicaments have been accomplished by 
the use of microcapsules, and more recently using biocompatible polymers utilizing the 
biodegradability to improve the controlled release of the medicament and the 
biocompatibility to avoid any rejection from the body.  
A polymer is considered biocompatible when the polymer itself or any degradation products 
of the polymer are non-toxic to the recipient and also present no deleterious or untoward 
effects on the recipient’s body. (Bernstein, Zhang, Khan, & Tracy, 1999). 1 
Biocompatible polymers are being widely used in biomedical applications, and more 
concretely in controlled drug release. The idea of controlled drug release from polymers 
dates back to the 1960s with the usage of silicon rubber as coating material made by 
Folkman and Long. Since this polymers had a low degradability and a bad biocompatibility, 
the requirement of surgical removement was needed and limited their applicability. Thus, 
biodegradable polymers and later both biodegradable and biocompatible polymers were 
tested and used for microencapsulation processes as microcapsules with this polymers 
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mentioned will not require a surgical removement or any measure of removal since it will be 
degraded and absorbed by the human body with no side effects.  
1.1. Background 
  
Previously, it has been studied the microencapsulation process and the control of it, as the 
encapsulation efficiency, the particle size, the control of sphere porosity, and the drug 
release rate. 2 as well as the preparation of microspheres from linear polymers and 
monomers. 
Regarding the encapsulation efficiency, Yang et al. 3 provided a revealing study which 
correlated encapsulation efficiency to sphere preparation temperature. The authors found 
that the highest encapsulation efficiencies occurred at the highest and lowest formation 
temperatures tested ( 50% at 4 and 38 ºC, and about 19% at  22 and 19ºC ). 
When considering the relation of the polymer to encapsulation efficiency Ghaderi et al. 4 
found that increasing the concentration of polymer in the organic phase increased the 
encapsulation efficiency.  
In the part concerning particle size, Yang et al. 3 reported that the size of the microsphere 
can be affected by the polymer concentration, temperature, viscosity, the stirring rate, and 
the amount of emulsifier employed. Considering the effect of polymer concentration,  it has 
been reported that increasing the concentration of the polymer in the second emulsion 
increases sphere size. 
In another study, Jeyanthi et al. 5 used a SEM to show that sphere size was temperature 
dependent; lower and higher temperatures produced larger spheres whereas intermediate 
temperatures produced smaller spheres. 
Also, several  studies reported that an increase of stirring rate produced smaller 
microspheres since finer emulsions were formed in the process.  
Finally, the control of sphere porosity, that has an important effect on drug delivery, could 
be managed by regulating the amount of water in the first w/o emulsion. Less water in the 
first emulsion led to a porosity decrease.  
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1.2. Motivation  
 
The motivation for the realization of this project comes from the introduction of the 
microencapsulation process by my project director, and the utility of biocompatible and 
biodegradable polymers in this field.  
Since this is a rising field with a lot of weight several industries as pharmaceutical, textile, 
medical, chemical, electronics and more, a lot of interest and motivation came up to me. 
As encapsulation of soluble drugs with certain biocompatible polymers have not been 
studied yet, this project will test the encapsulation process with caffeine as a soluble drug, 
and chitosan as coating polymer, adding several variables and changes to see how it effects 
to the process. 
 
1.3. Objectives 
 
In this final degree project the main objectives are to study the viability of the 
microencapsulation of soluble drugs with a biocompatible polymer, chitosan and to analyze 
the drug delivery of the system and the effect of the tissue when it is impregned by the 
mentioned microcapsules.  
For the study of the microencapsulation viability, various surfactants and cross-linking agents 
have been tested to see their effect on the process.  
Since there is no feedback in the field, a first approach of the encapsulation of soluble drugs 
with chitosan will be done without totally affirming the results obtained, at least until more 
research is done. 
Other secondary objectives are taken in this project, as the accomplishment of proper 
calibration curves for the caffeine system in order to calculate the encapsulation efficiency, 
or understand and apply the knowledge of surfactants and cross-linking agents in order to 
achieve the best encapsulation process. 
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2. THEORETICAL FRAMEWORK 
2.1. Microencapsulation 
 
Microencapsulation is a process in which active substances are coated by extremely small 
capsules. It is a new technology that has been used in the cosmetics industry as well as in 
the pharmaceutical, agrochemical and food industries, being used in flavors, acids, oils, 
vitamins, microorganisms, among others. The success of this technology is due to the 
correct choice of the wall material, the core release form and the encapsulation method.  
The polymer acts as a protective film, isolating the core and avoiding the effect of its 
inadequate exposure. This membrane dissolves itself through a specific stimulus, releasing 
the core in the ideal place or at the ideal time. 6 There are different types of microcapsules 
referring to their structure and terminology. 
Table 1 Terminology of microencapsulation products 7 
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The microcapsules also can be classified by their morphology in three basic categories as 
monocored, poly cored or matrix type. 
 
Monocored microcapsules have a single hollow chamber within the capsule. The poly core 
microcapsules have a number of different sized chambers within the shell. The matrix type 
microparticle has the active ingredients integrated within the matrix of the shell material. 
However, the morphology of the internal structure of a microparticle depends  largely  on  
the  selected  shell  materials  and  the microencapsulation  methods  that  are  employed. 8 
 
 
Figure 1 Types of microcapsules 8 
 
In the microencapsulation processes, several variables are taken into consideration to 
maximize the entrapment efficiency, the surface morphology, structure of the microcapsule 
or the size of it as is shown in the next figure 
Figure 2 microencapsulation parameters 10 
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2.1.1. Technics of microencapsulation 
 
Microencapsulation techniques consist basically on the emulsion of the active compound in 
a solution of the coating material.  The encapsulation of this active compound is achieved by 
modifying the continuous phase, changing parameters or with a chemical agent. 
The types of emulsions are: 
• w/o emulsion 
• o/w emulsion 
• w/o/w emulsion 
• o/w/o emulsion 
Generally, microencapsulation methods are divided into two basic groups, namely chemical 
and physical, with the latter being further subdivided into physico-chemical and physico-
mechanical techniques. This article describes the most generally accepted classification of 
the microencapsulation methods. 9 
 
Chemical process Pysico-chemical process Physico-mechanical process 
Polymerization Coacervation Spary-drying and 
congealing 
Interfacial 
polycondensation 
Solvent evaporation Electrostatic encapsulation 
 Layer-by-layer absortion Pan coating 
 Complex precipitation Vacuum encapsulation 
 Ionic gelation Extrusion 
 Supercritical fluid 
precipitation 
Air suspension 
 
  Multiorifice-centrifugal 
Table 2 Methods of microencapsulation 
In this project, the technic used is solvent evaporation method. Thus, a deeper explanation 
of the method is needed. 
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Firstly, we have to differentiate the phases of the process. The continuous phase, containing 
the surfactant or anti-foam agent, the disperse phase, which contains the polymer, that is in 
charge of the coating process, and finally the drug solution. 
The basics phenomenology of the microencapsulation process is simple. 
When the oil phase is formed, as is a microemulsion, the first step is taken. This 
microemulsion is basically little drops of the polymer with the solvent. After that, the drug 
solution is dispersed with the oil (or disperse) phase and the w/o emulsion is obtained, in 
which the polymer is mixed with the drug solution. 10 
Subsequently, the w/o phase is added to the continuous phase, and stirred at high rpm ( 10-
20 k rpm). Thus, the surfactant, that have both a hydrophilic and hydrophobic part, 
surrounds the w/o phase in a certain structure called micelles because the surfactant covers 
the surface of the w/o drops with the hydrophobic part in the drop, and the hydrophilic part 
in the water. 
Finally, the evaporation of the solvent is carried in continuous stirring during 8 hours. Once 
the solvent is completely evaporated, the polymer entrapped inside the micelle chemically 
interacts with the drug and is settled around the drug molecule creating a coating and 
consequently, forming the microcapsule.10 
 
 
Figure 3 Steps of solvent evaporation method 10 
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2.1.2. Applications of microencapsulation 
 
The reason for microencapsulation is basically to protect the encapsulated material from the 
environment through which it passes without and ensuring that the encapsulated material 
reaches the area of action. 
The main reasons for the use of this technic are the following ones: 
• controlled release of the encapsulated material 
• increased protection for the encapsulated material 
• works as a mask for odors, taste and interactions with external elements 
• protection of the environment 
Due to this multiple reasons microencapsulation has been widely used in several fields. For 
instance, medical and pharmaceutical purposes, biotechnology, chemical materials, textile 
and printing industries, electronics, water treatment, construction materials and many more. 
Since the introduction of microencapsulation in the 1950s in the paper industry, it has been 
improved, modified, researched and extended until now, and still has much way to go. 
The growth of microencapsulation process is shown in the increasing number of scientific 
articles, patents and industrial research.  
 
Figure 4 Growth of microencapsulation 7 
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2.2. Drug release 
 
Drug release could be described as the application of physical, chemical and biological 
principles for transporting drug molecules for clinical benefit. 
It encompasses all the approaches, formulations, technologies and systems for the control of 
the temporal and spatial location of drug molecules. 
When drugs are delivered using typical delivery systems as oral or injection methods, only a 
small part of the dose actually reaches the site of action, and the majority of the dose is 
wasted because it’s destroyed on the way, or goes to the wrong site of action. 
The aim of the controlled release is, in fact, really simple. It is based on getting the right 
amount of active agent in the right place, and at a certain time.  It has been really useful to 
extend medical dosage and reduce or remove the concentrations exceeding the therapeutic 
requirements. 11 
 
In temporal control, drug delivery systems aim to deliver the drug over an extended 
duration or at a specific time during treatment. Controlled release over an extended 
duration is highly beneficial for drugs that are rapidly metabolized and eliminated from the 
body after administration.  
Comparing concentrations in a case where a drug is delivered via injections versus a 
controlled release system , we can see the obvious benefits, since drug concentrations 
fluctuate widely during the several administrations via injection, and for only a portion of the 
treatment, the drug concentration is in the therapeutic range. (figure 1) 
With the controlled release system, the rate of drug release equals the rate of elimination of 
the drug, thus, the drug concentration is in the therapeutic range for mostly of the 
treatment.  
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Figure 5 Drug concentration along time  12 
 
2.2.1. Encapsulating coating materials 
 
The coating material should be capable to create a film around the core material/active 
compound, and being non-reactive and chemically compatible with it. Moreover, it has to 
provide some desired properties such as strength, impermeability, flexibility and sometimes, 
antimicrobial effects, as chitosan does. 
The use of polymers for coating in microencapsulation first started back in the 1960s, firstly 
using silicon rubber and polyethylene, but their lack of degradability of this Systems lead to 
further research in obtaining better materials for this function, with a higher degradability 
capacity. 12 
Classification of polymers in controlled drug release can be generally  divided in two groups, 
biodegradable or nonbiodegradable.  
Biodegradable Systems have garnered much of the attention in drug delivery Systems since 
nonbiodegradable Systems need retrieval or further manipulation after introducing it into 
the body. 
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Also, polymers can be classified by their mechanism of erosion. “Degradation” refers to 
bond cleavage, whereas “erosion” refers to depletion of the coating material. Degradation is 
a chemical process, while erosion is a physical phenomenon reliant on dissolution and 
diffusion processes. 12 
If the microcapsules are destined to a bioactivity such as medical or pharmaceutical purpose, 
then it is desired the biocompatibility of the polymer. This can be achieved by using natural 
polymers. For example, chitin ( and chitosan ), cellulose, lactic and glycolic acid. 
The range of polymers used in controlled drug delivery are shown in the following table 
based on the backbone composition. 
Table 3 summary of polymer structures based on backbone structures12 
 
  
12 
 
 
 
 
 
 
 
 
 
  
13 
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The most usual polymer in microencapsulation Is PLA and PLGA, due to their 
biodegradability and biocompatibility, but in this project the polymer used will be chitosan,  
offering an appropriate biodegradability and an excellent biocompatibility and antifungal 
activity thanks to its natural provenance. And as long as we are working in the scope of 
controlled drug released for human skin, the most suitable polymer will be one that has an 
excellent biocompatibility. 
Chitosan is produced by deacetylation of chitin, a structural element in the shells of shrimps 
and crabs. Chitosan is a cationic linear polysaccharide composed basically of β(1→4) linked 
glucosamine units together with some proportion of N-acetylglucosamine units. 13. 
 
 
 
 
 
 
                                     Figure 6 chitosan structure12 
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It must be pointed out that the microstructure of chitosan depends on whether the  
deacetylation reaction was carried out under homogeneous or heterogeneous conditions. 
This structural difference is very important in determining many properties of chitosan, such 
as solubility. Chitosan obtained by a heterogeneous procedure is not soluble in water, 
whereas water-soluble chitosan can be prepared by homogeneous deacetylation of chitin. 
Chitosan has an excellent film-forming ability. Chitosan films exhibit limited swelling in water. 
However, through the formation of blends and interpenetrated or semi interpenetrated 
polymer networks with highly hydrophilic polymers such as poly(vinyl alcohol), 
polyvinylpyrrolidone membranes with varying degrees of hydrophilicity have been obtained 
and used as matrices for different applications.13. 
 
2.2.2. Active compounds: 
 
The active compound tested in this project is caffeine, a natural alkaloid and  a soluble drug 
with the following chemical formula: C8H10N4O2. Is a central nervous system stimulant, and 
the world’s most widely consumed psychoactive drug due to is found in most of our daily 
products and diets, such as drinks as coffee and tea, chocolate and other soft drinks. 11 
It is found in nuts, seeds, or leaves of a number of plants from Africa, Asia or South America, 
but the most well-known source of caffeine is the coffee bean, a misnomer for the seed of 
coffee plants. 11 
Concerning it chemical properties, caffeine is odorless, colorless, and bitter powder. It is very 
soluble in water, reaching 16 mg/mL at 25ºC. 
It has a molar mass of 194,2 g/mol a density of 1.23 g/cm3 and a melting point of 235ºC. 
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The elimination half-life time in a normal human body goes from 3-7 hours in adults, to 65-
130 hours for a child, and the duration of action is held between 3-4 hours. 14 
 
2.2.3. Surfactants  
 
Some compounds, like short-chain fatty acids, are amphiphilic or amphipathic, i.e., they have 
one part that has an affinity for nonpolar media and one part that has an affinity for polar 
media. These molecules form oriented monolayers at interfaces and show surface activity 
(i.e., they lower the surface or interfacial tension of the medium in which they are dissolved). 
In some usage surfactants are defined as molecules capable of associating to form micelles. 
These compounds are termed surfactants, amphiphiles, surface-active agents, tensides, or, 
in the very old literature, paraffin-chain salts. The term surfactant is now probably the most 
commonly used and will be employed in this book. This word has a somewhat unusual 
origin, it was first created and registered as a trade- mark by the General Aniline and Film 
Corp. for their surface-active products. The company later released the term to the public 
domain for others to use . Soaps (fatty acid salts containing at least eight carbon atoms) are 
surfactants. Detergents are surfactants, or surfactant mixtures, whose solutions have cleaning 
properties. That is, detergents alter interfacial properties so as to promote removal of a 
phase from solid surfaces. 15 
The unusual properties of aqueous surfactant solutions can be ascribed to the presence of a 
hydrophilic head group and a hydrophobic chain (or tail) in the molecule. The polar or ionic 
head group usually interacts strongly with an aqueous environment, in which case it is 
Figure 7 Caffeine chemical structure 23 
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solvated via dipole-dipole or ion-dipole interactions. In fact, it is the nature of the polar head 
group which is used to divide surfactants into different categories. 15 
 
In aqueous solution dilute concentrations of surfactant act much as normal electrolytes but 
at higher concentrations very different behavior results. This behavior is explained in terms 
of the formation of organized aggregates of large numbers of molecules called micelles, in 
which the lipophilic parts of the surfactants associate in the interior of the aggregate leaving 
hydrophilic parts to face the aqueous medium. The formation of micelles in aqueous 
solution is generally viewed as a compromise between the tendency for alkyl chains to avoid 
energetically unfavorable contacts with water, and the desire for the polar parts to maintain 
contact with the aqueous environment. 15 
A thermodynamic description of the process of micelle formation will include a description 
of both electrostatic and hydrophobic contributions to the overall Gibbs energy of the 
system. Hydrocarbons (e.g., dodecane) and water are not miscible; the limited solubility of 
hydrophobic species in water can be attributed to the hydrophobic effect. The hydrophobic 
Gibbs energy (or the transfer Gibbs energy) can be defined as the difference between the 
standard chemical potential of the hydrocarbon solute in water and a hydrocarbon solvent 
at infinite dilution. 15 
 
 
 
Where the terms on the right side of the equation are the chemical potentials of the 
Hydrocarbon dissolved and water, respectively. 15 
 
 
 
 
Equation 1 Gibbs energy equation 15 
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2.2.4. Release mechanisms: 
 
Several release mechanisms have been developed to achieve temporal and distribution 
controlled release of drug using polymers. That’s because of the fact that many different 
drugs are used in controlled release and impose various restrictions on the type of delivery 
system used. Moreover, the environmental conditions or the release time directly influences 
on the appropriate mechanism in each case. 
An important part of the drug delivery process, is to take into account the fact that  the 
polymer is still wandering around the site of action. Here’s where natural or biodegradable 
polymers gain weight. These polymers may be excreted directly via kidneys, or reduced into 
smaller molecules that are then excreted. 12 
Also, it's important to consider the number of physicochemical properties that a polymer 
offers, concerning the different mechanisms of controlled release. The more 
physicochemical properties, the more mechanisms could be carried with a certain polymer. 
12 
The mechanisms can be divided in two groups, temporal controlled and distribution 
controlled. 
- Temporal controlled: Polymeric devices that achieve temporal controlled release protect 
the active compound from the environmental conditions for an expected period of time, 
attaining the desired concentration of drug during this period of time. 
This protection can involve delaying the dissolution of the active compound , inhibiting the 
diffusion of the active compound out of the microcapsule, or controlling the flow of active 
compound.  
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Figure 8 Examples of mechanisms of temporal controlled release12 
 
-Distribution controlled:  
The simplest method of distribution controlled, is to simply to directly apply the delivery 
device/tissue at the site of action. 
For majority of diseases that require distribution controlled release of a drug, a targeting 
mechanism is needed for the delivery system to reach the desired target.  
It exists two types of delivery systems depending on the polymer, colloidal carriers and 
polymer-drug conjugates. 
In colloidal carrier type, encapsulation consists in the polymer encapsulating the drug within 
micro/nano-capsules, whether in polymer-drug conjugates the drug is coupled to the 
polymer. 
Nevertheless, the polymer is functioning only as a carrier and is not in charge of targeting 
the delivery device, other biological molecules are used for targeting instead.12 
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2.2.5. Models of drug release: 
In drug release, exists several kinetic models that expect to control drug release of a delivery 
device, and are generally governed by zero or first order. 
In spite of all the models of drug release, in this project we will work with the most important 
three, Higuchi equation, power law, and Korsenmeyer-Peppas equation approximation. 
 
Higuchi equation:  
In 1961, Higuchi published probably the most famous and most often used mathematical 
equation to describe the release of drugs from matrix systems. On the beginning, it was only 
for planar systems, but was later improved and extended for other geometries and matrix. 
The classical Higuchi equation  was derived under pseudo-steady state assumptions and 
generally cannot be applied to real controlled release systems. 16 
The primary Higuchi equation is:  
 
Equation 2 Higuchi equation 16 
 
Mt: cumulative absolute amount of drug released at time t 
A: Surface area of the controlled release device 
D: drug diffusivity in the polymer carrier 
Co: Initial drug concentration  
Cs: solubility of the drug in the polymer 
Equation 2 can be expressed as: 
 
                                                          Equation 3 Higuchi equation simplified 16 
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M∞: absolute cumulative amount of drug released at infinite time ( equal to absolute 
amount of drug incorporated at time t=0) 
K: constant reflecting the design variables 
The simplicity of this equations is a good point for drug delivery systems, although some 
previous considerations must be taken into account: 
 
• The initial drug concentration in the system is much higher than the solubility of the 
drug 
• Mathematical analysis is based on one-dimensional diffusion. Thus, edge effects 
must be negligible. 
• The suspended drug is in a fine state such that the particles are much smaller in 
diameter than the thickness of the system 
• Swelling or dissolution of the polymer carrier is negligible. 
• Perfect sink conditions are maintained. 
• The diffusivity of the drug is constant. 16 
 
Power law: 
Power law is an equation for drug delivery, more comprehensive and still very simple, used 
to describe drug release from polymeric systems. The Power law equation is: 
 
Equation 4 Power law 16 
 
Mt: cumulative absolute amount of drug released at time t 
M∞: absolute cumulative amount of drug released at infinite time 
K: constant incorporating structural and geometric characteristics of the device. 
n: release exponent (indicative of the mechanism of drug release) 
  
23 
 
It is clear from equation 4 that when the exponent n takes a value of 1.0, the drug release 
rate is not linked to  time. This case corresponds to zero-order release kinetics. For slabs, the 
mechanism that creates the zero-order release is known among polymer scientists as case-II 
transport. Here the relaxation process of the macromolecules occurring upon water 
imbibition into the system is the rate-controlling step. Water acts as a plasticizer and 
decreases the glass transition temperature of the polymer. Once the T equals the 
temperature of the system, the polymer chains undergo the transfer from the glassy to the 
rubbery state, with increasing mobility of the macromolecules and volume expansion. 16 
Thus, equation 4 has two distinct physical realistic meanings in the two special cases of 
n=0.5 (indicating diffusion-controlled drug release) and n=1.0 (indicating swelling-controlled 
drug release). Values of n between 0.5 and 1.0 can be regarded as an indicator for the 
superposition of both phenomena (anomalous transport). It has to be kept in mind that the 
two extreme values for the exponent n, 0.5 and 1.0, are only valid for slab geometry. 16 
Peppas and Sahlin model: 
The equation developed by Peppas and Sahlin is the following one: 
 
Equation 5 Peppas and Sahlin equation 16 
K1, k2, m: constants  
The first term on the right side of the equation 4 represents the Fickian diffusional 
contribution, F, whereas the other term of the right side represents the case-II relaxational 
contribution, R. 16 The ratio of both contributions can be calculated as follows: 
 
Equation 6 Simplified Peppas and Sahlin equation 16 
This three models are the most commonly used in the modelling of drug release 
mechanisms due to their simplicity and comprehension. 16 
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3. RESEARCH APPROACH 
 
In this part, everything involved with the procedural part will be explain, including materials 
used, experimental methods and technics applied during the project. 
 
3.1. Materials 
 
3.1.1. Polymers and active agents 
 
Initially, the project was willing to be carried out with an aqueous solution of a therapeutic 
mushroom, commonly used in Eastern countries, such as China or Malaysia, but due to the 
extremely late delivery of it from the associated company this aqueous solution was replaced 
by caffeine. 
• Polymer: the polymer used in this project, as is mentioned before, is a high 
molecular weight chitosan. A high molecular weight chitosan is chosen in order to 
increase the solubility of it on DCM ( dichloromethane ) due to chitosan has a low 
solubility on organic and inorganic solvents. The chitosan used is 99% deacetylated , 
thus a 99% pure. 
 
• Active agent: The active agent encapsulated is caffeine, in a 99% purity. 
 
3.1.2. Surfactants and solvents 
 
In this project two different surfactants are used and compared in terms of efficiency of 
microencapsulation of the active agent. 
The two surfactants used are PVA ( poly vinyl alcohol ) and TWEEN 20 ( or polysorbate 20 ). 
The surfactants are used in order to form the initial micelles that will become the 
microcapsules. 
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The PVA used is originally in solid form, so we first have to make a solution with water, as 
well as TWEEN 20, but tween is in liquid form instead. 
 
3.1.3. Laboratory material 
 
Concerning the material used from the laboratory, the most used materials during the 
experimental part were, beakers, balances, volumetric flasks, test tubes, dropper pipet, 
pipets, stirring rods, graduated cylinder, spatula, wash bottle with distilled water. 
 
3.1.4. Textile substrates 
 
The two substrates used and compared in the drug delivery are cotton and PES (  polyester 
), since both are ones of the most commonly substrates used. 
During the drug delivery, the both tissues are compared, analyzing the concentration of 
active agent released in a serum solution along time. 
 
3.2. Equipment used 
 
Since this is a basically an experimental project, many equipment were used during it. 
Firstly, for the microemulsions made in the encapsulation process, an ultra turrax, a 
dispersing instrument that reaches 24.000 RPM, that allows the needed microemulsions, for 
the later microcapsules. 
For the analysis of the efficiency of the encapsulation process measured by absorbances, the 
UV-visible spectrometry  technic was used with the SHIMADZU UV2401PC UV-vis and the 
UVProve 2.43 software. 
  
26 
 
For the analysis of the shape and distribution of the microcapsules, an optic microscope was 
used. The model used is…… 
Also, we used a centrifuge to separate the liquid phase from the microcapsules and the 
remaining solids, in order to use the liquid for the efficiency analysis. 
Finally,  
 
3.3. Experimental methods and technics 
 
All the methods and technics used in the project will be explained in this part. 
 
3.3.1.  Preparation of microcapsules 
 
All the microcapsules were done by a double emulsion w/o/w and ending with the solvent 
evaporation method. 
Starting by solving the polymer, chitosan in this project, with DCM (dichloromethane) at low 
temperature to increase solubility. Due to the bad solubility of chitosan, a mechanical 
agitation was needed ( IKA T25 ) for a specific time.  
Simultaneously, the active compound, caffeine, is solved in water in a magnetic stirrer and 
then added to the polymer emulsion, to form the first simple emulsion w1/o (using Ultra 
turrax T25). 
Then, this simple emulsion w1/o is added to the continuous phase, that consists on PVA 
solved in water 2% w/w, and emulsified for several minutes to obtain the double emulsion 
w1/o/w2. 
Lastly, the mixture was maintained under constant agitation with a magnetic stirrer until all 
the solvent is evaporated and, in consequence, all the microcapsules formed 
3.3.2. Characterization of microcapsules 
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For the characterization of the microcapsules formed, several tests were done to determine, 
the efficiency of the encapsulation, the efficiency of the drug release, form and size of the 
microcapsules. The tests are the following ones: Encapsulation efficiency ( via UV-
Spectrophotometer ), particle size distribution, optical microscope and TGA ( 
thermogravimetric analysis) . 
 
3.3.2.1. Encapsulation efficiency 
 
The encapsulation efficiency of the microcapsules was measured indirectly in the liquid 
phase of the microcapsules mixture with the UV/vis spectrophotometer. An important 
previous step, is to centrifugate the solution/mixture of the liquid phase in order to minimize 
the interferences of remaining solids. The ratio of drug encapsulation is calculated by the 
following equation:  
 
Equation 7 Efficency equation 
Where Cf is the concentration measured in the liquid phase, and Ci is the initial 
concentration of drug before the microencapsulation process. 
Thus, it evaluates the difference of concentration of the drug before and after the 
microencapsulation process. 
 
3.3.2.2. Optical microscope 
 
The optical microscope is used in order to have a close view of the shape and size of the 
microcapsules obtained. To do this test, some drops of the microcapsules solutions are 
deposited on microscope slide and then some time is needed to let the sample dry 
Once the sample is dried it is analyzed with the microscope and thanks to the software that 
is attached to it, we can measure the size of some microcapsules.  
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3.3.2.3. Particle size distribution and zeta potential 
 
Particle size distribution is a characterization technic that analyzes the size of nanoparticles 
and the molecular size form less than one nanometer to some micras with DLS dynamic 
light technology. 17 
The particle size distribution of microcapsules was done at Malvern Nanosizer                              
( Nano-ZS Series ). The samples of microcapsules were introduced in the zeta cells and the 
results were reported as an intensity size distribution.  
 
Figure 9 Zeta sizer nano zs 18 
 Zeta potential is a scientific term for electrokinetic potential in colloidal systems. This term 
expresses the potential difference between the dispersion medium and the stationary layer 
of fluid attached to the dispersed particle.  19 
 
 
3.3.3. Impregnation and Drug release 
 
The last part of the experimental procedure consists in adding the microcapsules to a certain 
tissue, and then analyzing the drug delivery of the system in a serum solution. 
Firstly,  some pieces of the tissues are made and weight, in order to estimate the 
microcapsules adhered to the tissue after the impregnation. 
After the weight of the tissue is taken,  the impregnation of the microcapsules to the tissue is 
made. In this project, a rudimentary process was done that consisted in applying on the 
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tissue several drops (3-4) of the microcapsules solution with a droplet, and then the 
impregnated tissue is left in a evaporator for approximately 2 hours. 
Once the tissue is dried, only the microcapsules adhered remains on the substrate. 
Therefore, the tissue can be weight and the difference between the weights of before and 
after impregnation, gives us the information of the microcapsules adhered. 
Subsequently, the tissue is left inside an Erlenmeyer flask with physiological serum at 37ºC 
with a thermostated water bath ( in order to simulate the human skin/body conditions ) and 
several samples are taken in certain periods of time. 
 
This samples are analyzed in the UV-spectrophotometer to evaluate the amount and the 
speed of release of the microencapsulated drug during the chosen period of time. 
This, allows to determine the best compatible tissue for the different microcapsules 
obtained, and see how the drug release works in every tissue. 
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4. EXPERIMENTAL PROCEDURE 
 
4.1. Preparation of microcapsules and characterization 
 
4.1.1. Preparation of microcapsules 
 
The preparation of the caffeine microcapsules were done under the solvent evaporation 
method with a double emulsion w1/o/w2. In order to compare the influence of the 
components, some variables were changed resulting in different microcapsules. 
The changes of components in the microencapsulation process were the following ones: 
• Chitosan as the coating polymer, PVA  as the surfactant.  
 
• Chitosan as the coating polymer, Tween 20 as the surfactant 
 
• Chitosan as the coating polymer, Tween 20 as the surfactant, and tannic acid as 
cross-linking agent. 
 
The type of materials and amounts used in the process and the experimental conditions and 
procedures are shown in the following tables 11: 
 
4.1.1.1. Chitosan with PVA 
 
The encapsulation with PVA was previously tested with DCE instead of DCM, since no DCM 
was available at the beginning of the project, but nevertheless, in comparison the 
encapsulation was better with DCM. 
The process followed was the solvent evaporation method with a double emulsion w1/o/w2 
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Table 4 Materials and amounts 
Polymer CHITOSAN 250 mg 
Surfactant PVA (Poly vinyl alcohol) 3,06 g 
Active compound CAFFEINE 83,2 mg 
Polymer solvent (o) DCM (Dichloromethane) 10 mL 
Surfactant solvent (w2) Distilled water 150 mL 
Active compound solvent (w1) Distilled water 10 mL 
 
The experimental conditions for this essay are the following ones. 
Table 5 Experimental conditions 
Solutions T 
(ºC) 
Stirrer Speed (RPM) Stirring time 
Active compound Room Magnetic 700 15 min 
Polymer 4 Ultra-turrax 
T25 
3.000-5.000 10 min 
Surfactant Room Magnetic 700 2 h 
W1/o emulsion 4 Ultra-turrax 
T25 
16.000 15 min 
W1/o/w2 emulsion 4 Ultra-turrax 
T25 
20.000 10 min 
Solvent evaporation Room Magnetic 400 8 h 
 
 
4.1.1.2. Chitosan with Tween 20 
 
The encapsulation with Tween 20 was done under the solvent evaporation method with a 
double emulsion w1/o/w2. The amount of Tween 20 used is due a 1:1 molar ratio with the 
active compound. 
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Table 6 Materials and amounts 
Polymer CHITOSAN 250 mg 
Surfactant Tween 20 (polysorbate 20)  0,225 g 
Active compound CAFFEINE 83,2 mg 
Polymer solvent (o) DCM (Dichloromethane) 10 mL 
Surfactant solvent (w2) Distilled water 150 mL 
Active compound solvent (w1) Distilled water 10 mL 
 
The experimental conditions for this essay are the following ones. 
Table 7 Experimental conditions 
Solutions T 
(ºC) 
Stirrer Speed (RPM) Stirring time 
Active compound Room Magnetic 700 15 min 
Polymer 4 Ultra-turrax 
T25 
3.000-5.000 10 min 
Surfactant Room Magnetic 700 2 h 
W1/o emulsion 4 Ultra-turrax 
T25 
16.000 15 min 
W1/o/w2 emulsion 4 Ultra-turrax 
T25 
20.000 10 min 
Solvent evaporation Room Magnetic 400 8 h 
 
 
4.1.1.3. Chitosan with tween 20 and Tannic acid 
 
This encapsulation process is exactly the same as the previous one with Tween 20, but with 
the cross-linking agent, Tannic acid. 
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During the addition/dosage of the tannic acid solution, a lot of care must be taken in order 
to not saturate the solution, otherwise the microcapsules will conglomerate and the 
microcapsules will become unusable and impossible to characterize. 
 
Table 8 Materials and amounts 
Polymer CHITOSAN 250 mg 
Surfactant Tween 20 (polysorbate 20)  0,225 g 
Active compound CAFFEINE 83,2 mg 
Polymer solvent (o) DCM (Dichloromethane) 10 mL 
Surfactant solvent (w2) Distilled water 150 mL 
Active compound solvent (w1) Distilled water 10 mL 
Cross-linking agent Tannic acid 0,35 g 
Cross-linking solvent Distilled water 50 mL 
 
Table 9 Experimental conditions 
Solutions T 
(ºC) 
Stirrer Speed (RPM) Stirring time 
Active compound Room Magnetic 700 15 min 
Polymer 4 Ultra-turrax 
T25 
3.000-5.000 10 min 
Surfactant Room Magnetic 700 2 h 
W1/o emulsion 4 Ultra-turrax 
T25 
16.000 15 min 
W1/o/w2 emulsion 4 Ultra-turrax 
T25 
20.000 10 min 
Solvent evaporation Room Magnetic 400 8 h 
Cross-linking solvent Room Magnetic 400 10 min 
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4.1.2. Characterization of microcapsules 
 
The conditions of each analysis process corresponding to the characterization are shown in 
each part, and were the same for all type of microcapsules. 
 
4.1.2.1. Encapsulation efficiency 
 
Encapsulation efficiency was done in order to analyze the amount of active compound 
entrapped during the microencapsulation process. Two steps are needed for the 
encapsulation efficiency. First one to centrifugate the samples, and then perform the 
Spectrophotometry in the UV/Vis Spectrophotometer.  
 
The experimental conditions for the encapsulation process are the following ones.  
 
Table 10 Centrifugation conditions 
CENTRIFUGATION RATE (rpm) 1.000 
CENTRIFUGATION TIME (min) 10 
 
The UV/Vis spectrophotometer conditions are specified in the table below. 
 
Table 11 UV/Vis spectrophotometer conditions 
              Parameters PVA Tween 20 Tween 20 + tannic 
acid 
Wavelength (nm)  273 273 273 
Cell Quartz Quartz Quartz 
Lightpath (mm)  10 10 10 
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The encapsulation efficiency of the three different microencapsulation essays are shown in 
the next table, where the maximum encapsulation efficiency was reached with the PVA 
encapsulation, and the lower encapsulation efficiency was obtained with the Tween 20 + 
Tannic acid encapsulation. 
Table 12 Encapsulation efficiencies 
Sample Encapsulation Efficiency (%) 
Chitosan with PVA   45 
Chitosan with Tween 20 43 
Chitosan with Tween 20 + Tannic acid 38 
 
The encapsulation efficiencies seem low, but since there are no studies on 
microencapsulation of soluble drugs with chitosan, we cannot compare whether the results 
are meaningful or if a higher values of encapsulation efficiency should be reached. 
 
 
4.1.2.2. Optical microscope 
 
The samples were analyzed under the optical microscope in order to have a close view of 
the microcapsules shape and a first approach of the size of them.  
The following images were taken by the microscope software. Low concentration of 
microcapsules are seen in the images because a little volume of microcapsules volumes 
were taken in order to have a clearer view of the microcapsules. 
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Figure 10 Microscope digital image from Chitosan with PVA microcapsules 
 
We can see that majority of the microcapsules observed have a spherical or semi-spherical 
shape, although some of the microcapsules have an oval shape. 
 
Figure 11 Microscope digital image from Chitosan with Tween 20 microcapsules 
 
Figure 12 Microscope digital image from Chitosan with Tween 20 and Tannic acid microcapsules 
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4.1.2.3. Particle size distribution and zeta potential 
 
The particle size distribution and zeta potential were done in a zeta sizer Malvern, the 
experimental conditions are described below. 
 
Table 13 Zeta sizer conditions 
Dispersant Water 
Cell ( Size distribution) DTS 0012 – Disposable sizing cuvette 
Cell ( Zeta potential ) DTS 1060 – Green disposable zeta cell 
T (ºC) 25 
 
The particle size and zeta potential of each encapsulation test are shown in the following 
figures. 
 
• Chitosan with PVA microcapsules: 
 
Figure 13 Size distribution by intensity and by volume of Chitosan with PVA microcapsules. 
The figure above shows two peaks in both size distribution analysis in the chitosan with PVA 
microcapsules. One peak in 128 nm with a 32% by intensity and 20,4% by volume, and the 
other peak in 666 nm with a 68% by intensity and 79,6% by volume. 
The average particle diameter is 666 nm, meaning that our particles are smaller than 1 
micrometers.  That shows, usually that there is a formation of different kind of aggregates . 
One of them with major proportion of PVA, due to the previous existence of nucleous of 
aggregation. 
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The polydispersity value is 0,689 which means the majority of microcapsules are not the 
same size. 
The zeta potential of the Chitosan with PVA microcapsules are shown in the next figure. 
 
Figure 14 Zeta potential of Chitosan with PVA microcapsules 
The figure 11 shows us the zeta potential of the sample, which has a peak value of -3,32 Mv. 
Lightly negative, means some colloids are formed, obviously they must be microcapsules. 
Zeta potential in systems like these, represents the most external layer of aggregation. When 
the value is so little, means that there is poor stability on the system formed.  
 
• Chitosan with Tween 20 microcapsules: 
 
Figure 15 Size distribution by intensity and by volume of Chitosan with Tween 20 microcapsules. 
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In the figure 12 it is seen that two peaks appear in size distribution by intensity and only one 
by volume. Since Polydispersity is 1, that means that the majority of the microcapsules have 
a similar size, we will follow the size distribution by volume graphic. 
This graphic shows a peak on 7,88 nm size with a 100% percentage. 
As in the former case, there are two different structures involved into the process. As well as 
with PVA, there has been two colloidal species formed. One of them, very little, and the 
other one, reaches a size very similar that the one in which formation PVA, was used. 
Effect of Surfactant, gives better distribution to the lower range of diameters, but it is still not 
enough to influence the second size of aggregates formed. 
 
 
Figure 16 Zeta potential of chitosan with tween 20 microcapsules 
 
The figure indicates a peak of zeta potential of 0,421 Mv from the sample 
 
 
 
• Chitosan with Tween 20 and Tannic acid: 
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Figure 17 Size distribution by intensity and by volume of Chitosan with Tween 20 and Tannic acid microcapsules 
 
Figure 14 shows clearly that the majority of the microcapsules are distributed in one particle 
size with a value of 7,34 nm. And with a polydispersity of 1, we can confirm the statement 
that the majority of the microcapsules have a similar size. 
Here is the join effect of surfactant and a low molecular weight polymer when mixed 
together with Chitosan. The chemical similarity between last one and tannic acid, allows the 
system to be better organized. The increase in the lower range of size, allows us to consider 
that the final microcapsules obtained, are nearly the diameter of nano-capsules. Stability of 
the hybrid system formed will be better understood when TGA would be applied to these 
samples. 
The zeta potential of the sample is represented in the next figure. 
 
Figure 18 Zeta potential of chitosan with tween 20 with Tannic acid microcapsules 
As in the other zeta potential graphics only one peak is represented, with a peak value of 
6,44 Mv.. 
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Zeta potential  increases, what means that the colloids formed are much more stable than 
before. Clearly, not all the microcapsules formed are stable enough, but probably, the more 
reduced diameter would be the responsible of the positive part of the zeta potential. 
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4.2. Analysis of Drug delivery 
 
4.2.1. Impregnation  
 
The first part of the drug delivery is the weight of microcapsules attached to the tissue, that 
is calculated with a simple subtraction of the tissue weight before and after the impregnation 
of the microcapsules.  The amount of microcapsules medium applied to the tissue is 5 ml.         
The results of the impregnation are shown below. 
• Chitosan with PVA microcapsules 
Table 14 Impregnation results chitosan with PVA microcapsules 
Tissue Initial weight (g) Final weight (g) % over weight 
Cotton  0,417 0,430 3,11 
Polyester  0,412 0,414 0,5 
 
As we can see in the table above, it seems that cotton has a better affinity to the 
microcapsules than polyester, in which the microcapsules attached to the fabric are really 
low. 
 
• Chitosan with Tween 20 microcapsules 
Table 15 Impregnation results chitosan with Tween 20 microcapsules 
Tissue Initial weight (g) Final weight (g) % over weight 
Cotton  0,488 0,497 1,84 
Polyester  0,493 0,498 1,01 
 
The results in the table 15 demonstrate that the impregnation with this sample are lower in 
cotton, but a bit higher in polyester. 
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• Chitosan with Tween 20 and Tannic acid microcapsules 
Table 16 Impregnation results chitosan with PVA and Tannic acid microcapsules 
Tissue Initial weight (g) Final weight (g) % over weight 
Cotton  0,430 0,439 2,01 
Polyester  0,437 0,439 0,45 
 
In the table above it is shown similar results as in the table 14, the sample with chitosan and 
PVA, but with a lower impregnation in cotton fabric. 
 
4.2.1.1. Results  
 
As we can see in the tables 14, 15, and 16 the impregnation on the fabric are in general really 
low. Also, the impregnation on cotton are higher than in polyester in all the samples tested. 
One of the most important characteristic parameters controlling the affinity of the fabrics 
with other components is the zeta potential, which plays an important role in the electrical 
characterization of the fabrics in wet processing. 11 
The affinity between fabric and microcapsules are directly matched with zeta potential. If the 
zeta potential of the fabrics are similar to the microcapsules, then a good affinity will be 
ensured and vice versa.20 
Table 17 Zeta potential of fabrics at pH 10 2021 
Tissue Zeta potential (mv) 
Cotton -24,5 
Polyester -60 
 
In the table above is shown the zeta potential of the cotton and polyester fabrics at pH 10. Is 
clear that the zeta potentials of the fabrics are much higher than the zeta potential of the 
microcapsules, therefore this low impregnation results are the ones expected. 
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Tissue Zeta potential (mv) 
Chitosan with PVA -3,32 
Chitosan with Tween 20 0,421 
Chitosan with Tween 20 and Tannic acid 2,39 
 
As long as the chitosan with PVA microcapsules are the ones with the higher zeta potential 
values, we can say that it is expected that this sample obtained the higher impregnation on 
the fabrics. 
 
4.2.2. Drug delivery essay  
 
Drug delivery essay consisted on submerging the impregned fabrics into a thermostated 
vessel inside an Erlenmeyer filled with Physiological serum at 37ºC. 
The experimental conditions of the drug delivery essay are shown below, and are the same 
for all the samples. 
 
Table 18 Drug delivery essay conditions 
Weight Sample (g) 0,4 – 0,5  
Volume of medium (mL)  60 
Medium Physiological serum 
T (ºC) 37 
 
Once the impregnation is done, the drug delivery essay can be started. For the essay, 1 ml of 
the serum will be extracted in a certain period of time; 1’ 3’ 5’ 7’ 10’ 15’ 30’ 45’ 60’ 120’. 
This samples are saved in test tubes in order to be posteriorly poured in an Erlenmeyer for 
analyzing them in the UV/Vis spectrophotometer for measuring the amount of caffeine 
released to the medium. 
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4.2.2.1. Results 
 
The results of the drug delivery essay will be treated following two different approaches.  
Experimental results, based on theoretical mechanisms of drug release and quantitative 
following semi-empirical equations for drug release.  
 
4.2.2.1.1. Experimental results 
 
From the results in the following tables ( figure 15 – 20 ) we can observe that the behavior of 
the two tissues are similar, but with some differences. Cotton tissue starts releasing a big 
amount of caffeine at the first minutes, once ten minutes have passed, concentration of 
caffeine remains stable or even decreases, following a bimodal behavior. 22.  
On the other hand, Polyester also has a quick release of the caffeine at the first minutes of 
the drug delivery, but instead of maintaining a constant concentration or even decreasing, 
keeps slowly increasing the amount of caffeine released to the medium or close to a 
constant concentration, following a bimodal behavior as well. 
This behavior could be explained by a re-absorption of the caffeine released to the medium 
by the cotton fabric, what would explain the decrease or the constant concentration of the 
bath along the time. 
 
 This re-absorption happens due to the zeta potential of the cotton, since cotton has a lower 
zeta potential value as caffeine has, makes it easier for caffeine to be re-absorbed by the 
cotton tissue.  
 
And as polyester has a higher zeta potential, caffeine has not such an affinity with the tissue 
and remains in the bath.  
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Figure 19 Kinetic release of Chitosan with PVA microcapsules with caffeine in Cotton 
 
We can see in the figure above, that the concentration peak is found in the first ten minutes, 
and then the concentration starts decreasing. 
 
Figure 20 Kinetic release of Chitosan with PVA microcapsules with caffeine in Polyester 
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In figure 16 there is a clear example of what was explained before. A first part of the drug 
delivery where the caffeine is quickly released and afterwards a part where the concentration 
keeps slowly rising. 
 
Figure 21 Kinetic release of Chitosan with Tween 20 microcapsules with caffeine in Cotton 
 
Figure 17 follows almost exactly the same kinetic behavior as in the figure 15. 
 
Figure 22 Kinetic release of Chitosan with Tween 20 microcapsules with caffeine in Polyester 
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In figure 18 we can see that the behavior is most similar to the ones with the cotton fabric, 
cause in the part of the drug delivery, the caffeine concentration starts to decrease. 
Although this could have happened because of a mistake in the measure of the 
concentration in the minute 30, which may be too high. 
 
 
Figure 23 Kinetic release of Chitosan with Tween 20 and Tannic acid microcapsules with caffeine in Cotton 
 
 
Figure 24 Kinetic release of Chitosan with Tween 20 and Tannic acid microcapsules with caffeine in Polyester 
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In figure 20 we can see that the behavior in this sample is almost the same as in figure 16, 
following the behavior described previously. 
 
4.2.2.1.2. Power law 
 
The results for Power Law equation for the different samples are shown in the next tables 
and graphics. 
It has taken in considerations the two behaviors of the drug release, and will be treated 
different. A focus in the first step, short times, will be done. 
Using the Power law equation, the value of the exponent n, indicates the type of mass 
transport calculated. 
- Chitosan with PVA microcapsules 
From equation 4. we can extract the value of the exponent n by logarithms, as shown in the 
following figure. 
 
 
Figure 25 n value of Power law; COTTON 
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When log (mt/m inf.) represented vs log time, the slope of the linear regression is the value 
of n. in this case the n takes a value of 0,0339, being an anomalous diffusion. 
 
 
Figure 26 n value of Power law; POLYESTER 
 
In the sample with the polyester tissue, the n has a value of 0.2552, so follows an anomalous 
diffusion. We can see that in polyester the n values are higher than in cotton.  
 
Table 19  n values obtained from fitting drug release experimental data to Power Law 
 
 
 
 
 
 
 
 
R² = 0,9225
y = 0,2552x - 0,4764
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log t
Fabric type n R2 Drug delivery system 
Cotton 0.0339 0.0833 Anomalous  difussion 
Polyester 0.2552 0.9225 Anomalous  difussion 
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- Chitosan with Tween 20 microcapsules 
 
 
Figure 27 n value of Power law; COTTON 
 
In this case, the n value is much higher than with the previous microcapsules sample in 
cotton, meaning that the chemicals interactions between tween 20 and the tissue are more 
favorable in the drug delivery essay than PVA. 
 
Figure 28 n value of Power law; POLYESTEr 
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In this microcapsules sample, as the one before, the n values in the polyester tissue are 
higher than in cotton. Also in figure 27, the n value is relatively close to 0.5, but lower, 
meaning an anomalous diffusion. 
 
Table 20  n values obtained from fitting drug release experimental data to Power Law 
 
 
 
 
 
- Chitosan with Tween 20 and Tannic acid 
 
Figure 29 n value of Power law; COTTON 
 
In this essay, both the n value and regression coefficient are really low. Therefore, this drug 
delivery is defined by two  really different trends, and following an anomalous diffusion. 
  
 
y = 0,0086x - 0,1025
R² = 0,002
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Fabric type n R2 Drug delivery system 
Cotton 0,1015 0,7085 Anomalous  difussion 
Polyester 0,3146 0,6486 Anomalous  difussion 
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Figure 30 n value of Power law; POLYESTER 
 
It is shown in the graphics that the regression coefficient in cotton tend to be much lower 
than in polyester tissues, meaning that in cotton tends to have a much more differenced 
bimodal behavior than in polyester, that have a similar behavior in both short and long 
times, as expected and explained before in the experimental results. 
Table 21 n values obtained from fitting drug release experimental data to Power Law 
 
 
 
 
4.2.2.1.3. Higuchi model and Korsmeyer-Peppas approximation  
 
Since the release mechanism of active compound follows a Fickian diffusion, the Korsmeyer-
Peppas approximation and Higuchi model are taken. 
In the Higuchi equation, equation 3., when (mt/m inf. ) vs √𝑡 is represented, the slope of 
the linear regression is the “KH”  value. 
The KH values of the experimental results are shown in the following tables and figures. 
y = 0,2132x - 0,3111
R² = 0,6224
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Fabric type n R2 Drug delivery system 
Cotton 0,0086 0,002 Anomalous  difussion 
Polyester 0,2132 0,6224 Anomalous  difussion 
  
54 
 
Once this value is obtained, the diffusion coefficient, D/δ2 can be calculated from the 
Korsmeyer-Peppas approximation for planar delivery systems: 
 
 
 
- Chitosan with PVA 
 
Figure 31 K value of Higuchi model COTTON 
 
The k value of the Higuchi model is the slope of the regression line. Since the regression 
coefficient of the line is really close to 1, we can assume that the model fits the experimental 
results. 
In the cotton tissue, the K value is 0,2441. Then the diffusion coefficient can be calculated. 
y = 0,2441x + 0,231
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Equation 8 Korsmeyer-Peppas approximation for planar systems 
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Figure 32 K value of Higuchi model POLYESTER 
 
In the figure 9, the K value is 0,2189, in the polyester tissue, a bit lower than in cotton tissue. 
Although it was said before that polyester had a more progressive release during time than 
cotton tissue, on short times we can see that the release is faster in cotton than in polyester 
in this microcapsules sample. This could be attached to the fact that higher weight of 
microcapsules were sticked to the tissue, so a larger concentration of caffeine could be 
released. 
 
Table 22 K and D/ δ2 values obtained from fitting drug release experimental data to Higuchi 
 
 
 
 
 
 
 
y = 0,2189x + 0,001
R² = 0,9981
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Fabric type Kh D/δ2 R2 
Cotton 0,2441 0,048 0,9981 
Polyester 0,2189 0,043 0,9981 
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- Chitosan with Tween 20 
 
Figure 33 K value of Higuchi model COTTON 
 
 
Figure 34 K value of Higuchi model POLYESTER 
 
In this microcapsules sample we can observe that the k value, and therefore, the diffusion 
coefficient value is higher in polyester than in cotton, but really close one to the other.  
As in the case before, this little difference could be explained because the weight attached 
to the tissues were more similar  than in the previous case, and as far as polyester has a 
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faster release of the caffeine solution, made polyester had a better diffusion coefficient than 
cotton. 
Table 23 K and D/ δ2 values obtained from fitting drug release experimental data to Higuchi 
 
 
 
 
- Chitosan with Tween 20 and Tannic acid 
 
Figure 35 K value of Higuchi model COTTON 
 
In the last sample, the graphics show that the K value is much higher in polyester than in 
cotton. Thus, the diffusion coefficient is higher in polyester than in cotton for this sample. 
Also this reveals that the diffusion coefficient in this sample for polyester, is the higher one 
obtained. This could be linked to zeta potential, since this sample microcapsules have the 
less zeta potential value and polyester the bigger one.  
Once they are in the bath system, they easily leave the tissue and start degradating0 instead 
of the capsules in the cotton tissue due they have a better affinity that make it more difficult 
for the microcapsules to leave the tissue. 
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Fabric type Kh D/δ2 R2 
Cotton 0,1964 0,038 0,9093 
Polyester 0,2377 0,046 0,9917 
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Figure 36 K value of Higuchi model POLYESTER 
 
Table 24 K and D/ δ2 values obtained from fitting drug release experimental data to Higuchi 
 
 
 
 
To conclude the drug delivery essay, we can ensure that zeta potential is an important fact 
to be taken into consideration, as is the most important phenomena in impregnation and 
has influence in drug release since rules the interaction between microcapsules and tissues. 
We can see that as the zeta potential is lower, the diffusion coefficient increases, though the 
impregnation percentage decreases, so an equilibrium must be found in order to optimize 
the impregnation of microcapsules in the tissue and the diffusion coefficient. 
 
 In this samples, generally the cotton tissues release a bigger amount of caffeine to the 
medium but with a smaller diffusion coefficient, a choose can be made in which tissue 
should be used depending on the type of release needed, a fester release with less 
concentration will need a polyester tissue and vice versa.  
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Cotton 0,1861 0,036 0,9822 
Polyester 0,4218 0,083 0,9959 
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5. CONCLUSIONS  
 
This project has focused on the microencapsulation of caffeine, a soluble drug, with 
chitosan, the comparison of different reagents to see their effect on encapsulation efficiency, 
particles size, shape, affinity and impregnation to the tissues and the release in the drug 
delivery. 
Firstly, The encapsulation efficiency of the samples are low, but since there is no feedback on 
the caffeine encapsulation with chitosan, we can compare the results obtained. Also, the 
better encapsulation efficiency was obtained in the samples with PVA, and the lower 
encapsulation efficiency with the tween 20 and tannic acid samples. 
Nonetheless, the smaller particles were obtained by the Tween 20 with tannic acid samples 
thanks to tannic acid, that as a cross-linking agent wrap the molecule and compressed the 
particle by cross-linking chitosan and therefore reducing the particle size. Is also seen that 
the PVA microcapsules sample have a relatively bigger microcapsules, so we can ensure the 
effect of different surfactants on the particle size since the Tween 20 microcapsules had a 
similar particle size as the Tween 20 with Tannic acid samples. To sum up, PVA will lead to 
bigger microcapsules and Tween 20 to smaller ones. Adding Tannic acid will make them 
even smaller. 
Concerning to impregnation on the tissue, it is shown in the results that, as the both tissues 
had a really high zeta potential, the samples with the bigger zeta potential lead to a better 
impregnation because the closer the zeta potential was, the better affinity between the 
tissue and the sample had. 
Since the tissue with the lower zeta potential was cotton, this tissue lead to higher 
impregnation of microcapsules and therefore, polyester had lower impregnations,  
Thus, the samples released different concentrations of caffeine in the medium, so 
concentration released can be controlled by the tissue, since the impregnation can be 
controlled. 
In the drug delivery essay, it is clear that chitosan with caffeine microcapsules have a 
bimodal behavior, the first one with higher release speeds, and the second one with a lower 
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release of the active compound. The difference between polyester and cotton was mainly 
the concentration of the active compound released, due to the impregnation, and the 
second behavior of the drug release. 
While cotton maintained an almost constant concentration of caffeine in the second 
behavior, polyester had an increasing concentration trend of the active compound. This is 
why the regression coefficients in the experimental results were much lower in cotton than in 
polyester. Also, cotton had a reabsorption phenomenon, that is what explains the constant 
concentration of caffeine in the second part of the drug release, as it reaches an equilibrium 
in the bath. 
 
5.1. Future outlook 
 
The main objective of this project is obtaining a controlled drug delivery system to release 
the desired drug in the right place at the right time for a desired period.  
The first issue that must focus on is the encapsulation efficiency, since many factors influence 
the encapsulation efficiency as mentioned in the introduction part and a lot of study is 
needed to define the better factors for higher encapsulation efficiency in this encapsulation 
process. 
Also, an important problem to be solved is the affinity between fabrics and microcapsules, 
since their zeta potentials are really different, the impregnation on the tissues are really low, 
and many microcapsules and tissue are not used. 
Finally, I would like to recommend for future researchers the help of analysis instruments as 
SEM ( Scanning Electron Microscopy ) to have a closer view of the microcapsules, and the 
microcapsules on the fabric. Also a TGA ( Thermogravimetric Analyzer ) to see the 
distribution of the layers around the active compound and see their degradation with 
temperature. 
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ATTACHMENT A 
 
BUDGET 
 
In the Attachment A the budget of the equipment cost, material, products and service 
needed for the accomplishment of the project is included. 
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Table 25 Services budget 
Budget:  Services 
Service Unity Tariff Nº of services Total 
UV/VIS Hour 65,00 € 100 6.500 € 
Zeta sizer Samples 85,00 € 18 1.530 € 
Optical microscope Hour 30,00 € 15 450 € 
   Total price  2.635 € 
 
Table 26 Material budget 
Budget: Material 
Material Units Price Total 
Lab coat 1 20 € 20 € 
Graduated pipette 5 ml 5 56 € 280 € 
Graduated pipette 10 ml 5 58 € 290 € 
Volumetric flask 25 ml 20 9,50 € 190 € 
Beaker 10 ml 3 5 € 15 € 
Beaker 50 ml 2 15 € 30 € 
Beaker 600 ml 1 50€ 50 € 
Beaker 250 ml 2 20 € 40 € 
Naturflex gloves 1 box x 100 5 € 5 € 
Stirring rod 3 15 € 45 € 
Test tubes 40 5 € 200 € 
Spatula 3 20 € 40 € 
Dropper 10 2 € 20 € 
Parafilm 100 X 75 mtrs 1 47,5 € 47,5 € 
  Total price 1.272,5 € 
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Table 27 Projector budget 
Budget: projector 
Projectors Price Hours Total 
1 15 € / h 1100 16.500 € 
 
Table 28 Chemical reagents budget 
 
Table 29 Total budget 
Total Budget 
Services 2.635 € 
Projector 16.500 € 
Material 1.272,5 € 
Chemical reagents 273,01 € 
 20.680,51 € 
 
Budget: chemical reagent 
Material Units Price Total 
Chitosan 500 g 
CAS: 9012-76-4 
1 51,60 € 51,60 € 
PVA 500 g  
CAS: 9003-20-7 
1 65,34 € 65,34 € 
Tween 20 1 kg 
CAS: 9005-64-5 
1 16,07 € 16,07 € 
Tannic acid 250 g 
CAS: 1401-55-4 
1 62,90 € 62,90 € 
DCM 1L  
CAS: 75-09-2 
1 29,40 € 29,40 € 
Physiological serum 
CAS: 7647-14-5 
1 21,60 € 21,60 € 
Caffeine 100 g 
CAS: 58-08-2 
1 26,10 € 26,10 € 
  Total price 273,01 € 
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ATTACHMENT B 
 
In this Attachment B the material safety data sheet of each chemical reagent will be added. 
The MSDS are all extracted from FISHER SCIENTIFIC. 
https://www.fishersci.com/us/en/catalog/search/sdshome.html 
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